The board of directors' explanation regarding this trade complies with the fourth provision of the "Regulatory Guidelines for Listed Companies No. 9 - Regulatory Requirements for Listed Companies Planning and Implementing the Issuance of Shares and Payment of Cash to Purchase Assets."
Board of directors' statement on the purchase and sale of assets by the listed company in the twelve months prior to this trade.
The board of directors explains that the entities related to this trade do not fall under the situations specified in Article 12 of the "Guidelines for the Supervision of Listed Companies No. 7 - Regulatory Measures for Abnormal Trading of Stocks of Listed Companies Involved in Major Asset Restructuring" and Article 30 of the "Self-Regulatory Guidelines for Listed Companies No. 6 - Major Asset Restructuring" issued by the Shanghai Stock Exchange.
An explanation from the board of directors on whether there is the direct or indirect hiring of other third-party institutions and individuals for this transaction.
The board of directors provides an explanation that this trade is in compliance with Article 11 and Article 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.
The board of directors stated that this transaction complies with the provisions of Article 11.2 of the Rules of the Shanghai Stock Exchange's Science and Technology Innovation Board for the Listing of Stocks, Article 20 of the Measures for the Continuous Supervision of Listed Companies on the Science and Technology Innovation Board (Trial), and Article 8 of the Rules for the Review of Major Asset Restructuring of Listed Companies of the Shanghai Stock Exchange.
Explanation from the board of directors regarding the fluctuations of the stock price in the 20 trading days prior to the first announcement of this transaction.
Explanation of the confidentiality measures and system adopted by the board of directors for this trade.
Explanation from the board of directors regarding whether this trade constitutes a major asset reorganization, related party transactions, and restructuring for listing.
The board of directors explains the completeness and compliance of the legal procedures for this trade, and the validity of submitting legal documents.
Instructions of the board of directors that this transaction complies with the provisions of Article 4 of the “Guidelines for the Supervision of Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructurings”
The Board's explanation on the completeness of the transaction's compliance with legal procedures and the effectiveness of submitting legal documents
The board of directors explained that the entities involved in this transaction did not have Article 12 of the “Supervisory Guidelines for Listed Companies No. 7 - Supervision of Abnormal Stock Transactions Related to Major Asset Restructurings of Listed Companies” or Article 30 of the “Shanghai Stock Exchange Listed Companies Self-Regulatory Guidelines No. 6 - Major Asset Restructurings”
Explanation of the board of directors on stock price fluctuations in the 20 trading days prior to the date of the first announcement of this transaction
Explanation of the board of directors on the purchase and sale of assets by listed companies within 12 months prior to this transaction
Explanation of the Board of Directors on the confidentiality measures and confidentiality system adopted in this transaction
Instructions of the board of directors that this transaction complies with the provisions of Articles 11 and 43 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
Explanation of the Board of Directors that this transaction does not constitute a restructuring and listing situation as stipulated in Article 13 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
The board of directors explained that the transaction complied with the provisions of section 11.2 of the “Shanghai Stock Exchange Science and Technology Innovation Board Stock Listing Rules”, section 20 of the “Measures for the Continued Supervision of Companies Listed on the Science and Technology Innovation Board (Trial)”, and section 8 of the “Shanghai Stock Exchange Listed Company Major Asset Reorganization Review Rules”
Sanyou Healthcare: 2021 Annual Equity Distribution Implementation Notice
No Data
No Data